Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

(2021) Yair Herishanu et al.   BLOOD

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

(2021) Lee M. Greenberger et al.   CANCER CELL

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

(2021) Sidse Ehmsen et al.   CANCER CELL

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

(2021) Ilies Benotmane et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

(2021) H. Parry et al.   Blood Cancer Journal

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

(2020) Francesca Romana Mauro et al.   LEUKEMIA

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

(2020) Christopher Pleyer et al.   BLOOD

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib may impair serological responses to influenza vaccination

(2017) Abby P. Douglas et al.   HAEMATOLOGICA

Ibrutinib may impair serological responses to influenza vaccination

(2017) Abby P. Douglas et al.   HAEMATOLOGICA

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

(2011) O. E. Yri et al.   BLOOD